Patient Square’s Enavate backs Camp4 in $100M series B, driving push to clinic
Six-year-old company advancing ‘regulatory RNA’ platform, ASO therapies preparing to start human testing of Dravet syndrome program next year
Antisense therapeutics developer Camp4 has chosen Patient Square’s new Enavate investment platform to lead its $100 million series B round, fortifying its balance sheet as its first two programs move toward the clinic.
“We see our investors as partners, who can help us think through the decisions we make and set us up for success,” President and CEO Josh Mandel-Brehm told BioCentury. “Patient Square has a track record of investing all the way to an approved product. That completely aligns with our long-term outlook.”...